Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $38M (up 16.0% year over year) with net income of −$36M.
Q3 2026 key financials · XBRL
- Revenue
- $38M
- +16.0% YoY · +12.0% QoQ
- Net income
- −$36M
- +30.4% YoY · +42.9% QoQ
- Operating margin
- -90.6%
- EPS (diluted)
- −$0.35
- +32.7% YoY · +44.4% QoQ
Source: XBRL data from the ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 10-Q on SEC EDGAR. USD.
ARS Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $37.7M, up $5.2M YoY from $32.5M, driven by higher global neffy unit sales
- Net loss $35.6M vs $51.2M YoY; operating loss $34.2M vs $53.2M
- Best performer: U.S. neffy product revenue $33.4M vs $31.3M; supply revenue $2.6M vs $1.1M
- Cash, equivalents and short-term investments $138.4M; operating cash use $139.6M for nine months vs $127.4M
- Outlook: resources expected sufficient until cash-flow breakeven; Phase 2b ARS-2 interim data expected first quarter 2027
Risk Factors
- Newly added trade risk: EU-sourced materials face potential pharmaceutical tariffs, with alternative qualification requiring 18-24 months
- Regulatory risk: Cipla filed paragraph IV challenges in March 2026, prompting ARS to sue in April 2026
- Commercial risk: Competitor Anaphylm’s NDA resubmission received FDA review, with a March 2027 target action date
- Financial risk: $125.0 million Credit Agreement balance, plus a $25.0 million minimum liquidity covenant
- Liquidity risk: Net loss $158.5 million and accumulated deficit $453.1 million as of September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARS Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.